Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab Ecteribulin (MORAb-202) vs Investigator's Choice Chemotherapy in Platinum-resistant Ovarian Cancer
NCT05613088Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2023
- Primary completion
- Jun 2024
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of farletuzumab ecteribulin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Objective Response Rate at 70 weeks and Number of Participants With Treatment-Related Adverse Event Leading to Discontinuation at 6 months. Started Feb 2023; status: terminated.
02
Drugs
farletuzumab ecteribulin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05613088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613088.